Trial
NCT01003938
Topotecan With Erlotinib for Topotecan Pretreated Ovarian Cancer
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
NYU Langone Health
Collaborators
OSI Pharmaceuticals
Condition
Ovarian Cancer
Intervention
Topotecan
Why stopped
due to administrative issue and financial sponsor decision to suspend ovarian cancer studies
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-06-30